Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 37.48% | 3.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 37.48% | 3.50% | |||
| Cost of Revenue | 5.06% | -44.51% | |||
| Gross Profit | 40.51% | 12.59% | |||
| SG&A Expenses | -3.63% | -21.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.06% | -14.58% | |||
| Operating Income | 24.04% | 19.52% | |||
| Income Before Tax | 27.87% | 24.88% | |||
| Income Tax Expenses | -311.72% | 260.00% | |||
| Earnings from Continuing Operations | 28.50% | 24.64% | |||
| Earnings from Discontinued Operations | -- | 262.55% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.26% | 43.44% | |||
| EBIT | 24.04% | 19.52% | |||
| EBITDA | 27.29% | 21.58% | |||
| EPS Basic | 14.82% | 45.75% | |||
| Normalized Basic EPS | 31.51% | 18.29% | |||
| EPS Diluted | 14.82% | 45.75% | |||
| Normalized Diluted EPS | 31.51% | 18.29% | |||
| Average Basic Shares Outstanding | 3.01% | 4.25% | |||
| Average Diluted Shares Outstanding | 3.01% | 4.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||